Eton & Aquestive Announce Exclusive LIBERVANT U.S. Licensing Agreement
Eton entered an exclusive licensing agreement with Aquestive for LIBERVANT buccal film, targeting a U.S. seizure rescue market exceeding $450 million annually with an anticipated April 2027 commercial launch.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed